Persistence and pathogenesis of the neurotropic polyomavirus JC

Annals of Neurology

Volumn 77, Issue 4, 2015, Pages 560-570

  Wollebo, Hassen S ^a   White, Martyn K ^a   Gordon, Jennifer ^a   Berger, Joseph R ^b   Khalili, Kamel ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS PROTEIN;

ASYMPTOMATIC INFECTION; BLOODSTREAM INFECTION; BRAIN INFECTION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM INFECTION; GENE EXPRESSION; GLIA CELL; HUMAN; IMMUNE EVASION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; JC VIRUS; KIDNEY INFECTION; LEUKOCYTE; LIFE CYCLE; NONHUMAN; PERSISTENT VIRUS INFECTION; POLYOMAVIRUS INFECTION; POLYOMAVIRUS JC INFECTION; PRIMARY INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY MECHANISM; REVIEW; VIREMIA; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; ANIMAL; BLOOD; EPIDEMIOLOGY; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; METABOLISM; TRANSMISSION;

ANIMALS; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; SEROEPIDEMIOLOGIC STUDIES;

EID: 84925644956     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24371     Document Type: Review

References (98)

1. Watanabe I, Preskorn SH,. Virus-cell interaction in oligodendroglia, astroglia and phagocyte in progressive multifocal leukoencephalopathy. An electron microscopic study. Acta Neuropathol 1976; 36: 101-115.
2. Del Valle L, Piña-Oviedo S,. HIV disorders of the brain: pathology and pathogenesis. Front Biosci 2006; 11: 718-732.
3. Berger JR,. The clinical features of PML. Cleve Clin J Med 2011; 78 (suppl 2): S8-S12.
4. Tavazzi E, White MK, Khalili K,. Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol 2012; 22: 18-32.
5. Chalkley JJ, Berger JR,. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep 2013; 13: 408.
6. Schwab N, Ulzheimer JC, Fox RJ, et al. Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control. Neurology 2012; 78: 458-467.
7. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68: 1156-1164.
8. Nagayama S, Gondo Y, Araya S, et al. Progressive multifocal leukoencephalopathy developed 26 years after renal transplantation. Clin Neurol Neurosurg 2013; 115: 1482-1484.
9. Zaheer F, Berger JR,. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf 2012; 3: 227-239.
10. Gheuens S, Pierone G, Peeters P, Koralnik IJ,. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 2010; 81: 247-254.
11. Tan IL, Koralnik IJ, Rumbaugh JA, et al. Progressive multifocal leukoencephalopathy in a patient without immunodeficiency. Neurology 2011; 77: 297-299.
12. Delgado-Alvarado M, Sedano MJ, González-Quintanilla V, et al. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci 2013; 327: 75-79.
13. Padgett BL, ZuRhein GM, Walker DL, et al. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1: 1257-1260.
14. White MK, Gordon J, Khalili K,. The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. PLoS Pathog 2013; 9: e1003206.
15. Frisque RJ, Bream GL, Cannella MT,. Human polyomavirus JC virus genome. J Virol 1984; 51: 458-469.
16. Khalili K, Gordon J, White MK,. The polyomavirus, JCV and its involvement in human disease. Adv Exp Med Biol 2006; 577: 274-287.
17. Van Loy T, Thys K, Ryschkewitsch C, et al. JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route. J Virol 2015; 89: 1340-1347.
18. Yogo Y, Kitamura T, Sugimoto C, et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol 1990; 64: 3139-3143.
19. Kitamura T, Sugimoto C, Kato A, et al. Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains. J Clin Microbiol 1997; 35: 1255-1257.
20. Bofill-Mas S, Clemente-Casares P, Major EO, et al. Analysis of the excreted JC virus strains and their potential oral transmission. J Neurovirol 2003; 9: 498-507.
21. Ault GS, Stoner GL,. Two major types of JC virus defined in progressive multifocal leukoencephalopathy brain by early and late coding region DNA sequences. J Gen Virol 1992; 73: 2669-2678.
22. Agostini HT, Ryschkewitsch CF, Mory R, et al. JC virus (JCV) genotypes in brain tissue from patients with progressive multifocal leukoencephalopathy (PML) and in urine from controls without PML: increased frequency of JCV type 2 in PML. J Infect Dis 1997; 176: 1-8.
23. Zheng HY, Takasaka T, Noda K, et al. New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy. J Gen Virol 2005; 86: 2035-2045.
24. Dang X, Vidal JE, Oliveira AC, et al. JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol 2012; 93: 175-183.
25. Richardson EP,. Progressive multifocal leukoencephalopathy. N Engl J Med 1961; 265: 815-823.
26. Du Pasquier RA, Corey S, Margolin DH, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003; 61: 775-782.
27. Koralnik IJ, Wüthrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57: 576-580.
28. Wüthrich C, Koralnik IJ,. Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2012; 71: 54-65.
29. Dang X, Wüthrich C, Gordon J, et al. JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant. PLoS One 2012; 7: e35793.
30. Agnihotri SP, Wuthrich C, Dang X, et al. A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient. Ann Neurol 2014; 76: 140-147.
31. Monaco MC, Jensen PN, Hou J, et al. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 1998; 72: 9918-9923.
32. Kato A, Kitamura T, Takasaka T, et al. Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsilar hypertrophy. J Neurovirol 2004; 10: 244-249.
33. Berger JR, Miller CS, Mootoor Y, et al. JC virus detection in bodily fluids: clues to transmission. Clin Infect Dis 2006; 43: e9-e12.
34. Del Valle L, White MK, Enam S, et al. Detection of JC virus DNA sequences and expression of viral T antigen and agnoprotein in esophageal carcinoma. Cancer 2005; 103: 516-527.
35. Dörries K, Vogel E, Günther S, Czub S,. Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals. Virology 1994; 198: 59-70.
36. Gallia GL, Houff SA, Major EO, Khalili K,. Review: JC virus infection of lymphocytes-revisited. J Infect Dis 1997; 176: 1603-1609.
37. Ciappi S, Azzi A, De Santis R, et al. Archetypal and rearranged sequences of human polyomavirus JC transcription control region in peripheral blood leukocytes and in cerebrospinal fluid. J Gen Virol 1999; 80: 1017-1023.
38. Chalkias S, Dang X, Bord E, et al. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 2014; 75: 925-934.
39. Jensen PN, Major EO,. Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. J Leukoc Biol 1999; 65: 428-438.
40. Houff SA, Major EO, Katz DA, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988; 318: 301-305.
41. Dubois V, Dutronc H, Lafon ME, et al. Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol 1997; 35: 2288-2292.
42. Chen NN, Kerr D, Chang CF, et al. Evidence for regulation of transcription and replication of the human neurotropic virus JCV genome by the human S(mu)bp-2 protein in glial cells. Gene 1997; 185: 55-62.
43. Johnson EM, Wortman MJ, Dagdanova AV, et al. Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy. Clin Dev Immunol 2013; 2013: 197807.
44. Lednicky JA, Butel JS,. Tissue culture adaptation of natural isolates of simian virus 40: changes occur in viral regulatory region but not in carboxy-terminal domain of large T-antigen. J Gen Virol 1997; 78: 1697-1705.
45. Atwood WJ, Amemiya K, Traub R, et al. Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology 1992; 190: 716-723.
46. Monaco MC, Atwood WJ, Gravell M, Major EO,. JCV infection of hematopoietic progenitor cells, primary B lymphocytes and tonsillar stromal cells: implications for viral latency. J Virol 1996; 70: 7004-7012.
47. Monaco MC, Sabath BF, Durham LC, Major EO,. JC virus multiplication in human hematopoietic progenitor cells requires the NF-1 class D transcription factor. J Virol 2001; 75: 9687-9695.
48. Marshall LJ, Dunham L, Major EO,. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol 2010; 91: 3042-3052.
49. Marshall LJ, Moore LD, Mirsky MM, Major EO,. JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes. J Gen Virol 2012; 93: 651-661.
50. Tan CS, Dezube BJ, Bhargava P, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009; 199: 881-888.
51. Berger JR, Houff SA, Major EO,. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009; 1: 583-589.
52. Major EO,. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35-47.
53. Frohman EM, Monaco MC, Remington G, et al. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014; 71: 596-602.
54. Saure C, Warnke C, Zohren F, et al. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol 2011; 68: 1428-1431.
55. Warnke C, Smolianov V, Dehmel T, et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 2011; 17: 151-156.
56. White MK, Khalili K,. Pathogenesis of progressive multifocal leukoencephalopathy-revisited. J Infect Dis 2011; 203: 578-586.
57. Pérez-Liz G, Del Valle L, Gentilella A, et al. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 2008; 64: 379-387.
58. Tan CS, Ellis LC, Wüthrich C, et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol 2010; 84: 9200-9209.
59. White MK, Safak M, Khalili K,. Regulation of gene expression in primate polyomaviruses. J Virol 2009; 83: 10846-10856.
60. Romagnoli L, Wollebo HS, Deshmane SL, et al. Modulation of JC virus transcription by C/EBPbeta. Virus Res 2009; 146: 97-106.
61. Wollebo HS, Safak M, Del Valle L, et al. Role for tumor necrosis factor-α in JC virus reactivation and progressive multifocal leukoencephalopathy. J Neuroimmunol 2011; 233: 46-53.
62. Nukuzuma S, Nakamichi K, Kameoka M, et al. TNF-α stimulates efficient JC virus replication in neuroblastoma cells. J Med Virol 2014; 86: 2026-2032.
63. Atwood WJ, Wang L, Durham LC, et al. Evaluation of the role of cytokine activation in the multiplication of JC virus (JCV) in human fetal glial cells. J Neurovirol 1995; 1: 40-49.
64. Manley K, O'Hara BA, Gee GV, et al. NFAT4 is required for JC virus infection of glial cells. J Virol 2006; 80: 12079-12085.
65. Wollebo HS, Melis S, Khalili K, et al. Cooperative roles of NF-κB and NFAT4 in polyomavirus JC regulation at the KB control element. Virology 2012; 432: 146-154.
66. Romagnoli L, Sariyer IK, Tung J, et al. Early growth response-1 protein is induced by JC virus infection and binds and regulates the JC virus promoter. Virology 2008; 375: 331-341.
67. Kim SY, Woo MS, Kim WK, et al. Glial cell-specific regulation of the JC virus early promoter by histone deacetylase inhibitors. J Virol 2003; 77: 3394-3401.
68. Wollebo HS, Woldemichaele B, Khalili K, et al. Epigenetic regulation of polyomavirus JC. Virol J 2013; 10: 264.
69. Beltrami S, Gordon J,. Immune surveillance and response to JC virus infection and PML. J Neurovirol 2014; 20: 137-149.
70. Koralnik IJ, Du Pasquier RA, Letvin NL,. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001; 75: 3483-3487.
71. Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127: 1970-1978.
72. Warnke C, Mausberg AK, Stettner M, et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology 2013; 81: 1400-1408.
73. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361: 1067-1074.
74. Korman BD, Tyler KL, Korman NJ,. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009; 145: 937-942.
75. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
76. Tan CS, Koralnik IJ,. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437.
77. Martin Mdel P, Cravens PD, Winger R, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009; 66: 1016-1020.
78. Small JA, Scangos GA, Cork L, et al. The early region of human papovavirus JC induces dysmyelination in transgenic mice. Cell 1986; 46: 13-18.
79. Haas S, Haque NS, Beggs AH, et al. Expression of the myelin basic protein gene in transgenic mice expressing human neurotropic virus, JCV, early protein. Virology 1994; 202: 89-96.
80. Kondo Y, Windrem MS, Zou L, et al. Human glial chimeric mice reveal astrocytic dependence of JC virus infection. J Clin Invest 2014; 124: 5323-5336.
81. Tretiakova A, Krynska B, Gordon J, Khalili K,. Human neurotropic JC virus early protein deregulates glial cell cycle pathway and impairs cell differentiation. J Neurosci Res 1999; 55: 588-599.
82. Darbinyan A, Kaminski R, White MK, et al. Polyomavirus JC infection inhibits differentiation of oligodendrocyte progenitor cells. J Neurosci Res 2013; 91: 116-127.
83. Del Valle L, Pina-Oviedo S,. HIV disorders of the brain: pathology and pathogenesis. Front Biosci 2006; 11: 718-732.
84. Mazlo M, Ressetar HG, Stoner GL,. The neuropathology and pathogenesis of progressive multifocal leukencephalopy. In:, Khalili K, Stoner GL,. Human polyomaviruses: molecular and clinical perspectives. New York: John Wiley & Sons, 2001: 257-336.
85. Sheremata W, Brown AD, Rammohan KW,. Dimethyl fumarate for treating relapsing multiple sclerosis. Expert Opin Drug Saf 2015; 14: 161-170.
86. Berger JR,. Progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep 2007; 7: 461-469.
87. Gordon J, Gallia GL, Del Valle L, et al. Human polyomavirus JCV and expression of myelin genes. J Neurovirol 2000; 6 (suppl 2): S92-S97.
88. Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84: 1499-1504.
89. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71: 115-123.
90. Kean JM, Rao S, Wang M, Garcea RL,. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5: e1000363.
91. Carter JJ, Madeleine MM, Wipf GC, et al. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 2003; 95: 1522-1530.
92. Verbeeck J, Van Assche G, Ryding J, et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008; 57: 1393-1397.
93. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199: 837-846.
94. Engels EA, Rollison DE, Hartge P, et al. Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer 2005; 117: 1013-1019.
95. Padgett BL, Walker DL,. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973; 127: 467-470.
96. Taguchi F, Kajioka J, Miyamura T,. Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 1982; 26: 1057-1064.
97. Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997; 176: 250-254.
98. Matos A, Duque V, Beato S, et al. Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 2010; 82: 494-504.